Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Viking Therapeutics Inc VKTX

Healthcare Biotechnology
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of therapies for treatment of metabolic and endocrine disorders. The Company's clinical programs include VK2809, an orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders, which is being evaluated in a Phase II b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. The Company is developing VK0214, which is also an orally available, tissue and receptor-subtype selective agonist of TRb for X-linked adrenoleukodystrophy (X-ALD), a rare X-linked, inherited neurological disorder characterized by a breakdown in the protective barriers surrounding brain and nerve cells. It is also developing VK2735, a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the treatment of various metabolic disorders.


NDAQ:VKTX - Post by User

Viking Therapeutics Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(233)
•••
Post by whytestockson Jun 27, 2024 1:30pm
51 Views
Post# 36109265

VKTX Price Target Alert: $105.00. Issued by Morgan Stanley

VKTX Price Target Alert: $105.00. Issued by Morgan Stanley
NEWS: $VKTX VKTX Price Target Alert: $105.00. Issued by Morgan Stanley2024-06-27 06:00:08 ET Michael Ulz from Morgan Stanley issued a price target of $105.00 for VKTX on 2024-06-27 04:57:00. The adjusted price target was set to $105.00. At the time of the announcement, VKTX was trading at $47.39. The overall price target consensus is at $9...VKTX - VKTX Price Target Alert: $105.00. Issued by Morgan Stanley

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities